Find a Doctor

ET
Areas of Expertise

Eric Thouvenot

Nîmes University Hospital
Male

Bio

Eric Thouvenot is in Nimes, France. They have been an author on 101 peer reviewed articles and participated in 9 clinical trials in the past 15 years.

Areas of Expertise

Contact

Nimes, FR

Latest Advances

Latest Advance
Study
  • Condition: Relapsing-Remitting Multiple Sclerosis
  • Journal: Neurology(R) neuroimmunology & neuroinflammation
  • Treatment Used: Cholecalciferol
  • Number of Patients: 181
  • Published —
The study researched the outcomes of Cholecalciferol in patients with relapsing-remitting multiple sclerosis.
Latest Advance
Study
  • Condition: Multiple Sclerosis
  • Journal: Neurology
  • Treatment Used: Teriflunomide (TRF) vs. Dimethyl Fumarate (DMF)
  • Number of Patients: 1770
  • Published —
This study compared the effectiveness of teriflunomide (TRF) and dimethyl fumarate (DMF) on both clinical and MRI outcomes in patients with multiple sclerosis.
Latest Advance
Study
  • Condition: Myelin oligodendrocyte glycoprotein antibodies (MOG-Ab)
  • Journal: Journal of neuroinflammation
  • Treatment Used: Immunosuppressant therapy
  • Number of Patients: 125
  • Published —
The study researched the safety and effectiveness of treatments in myelin oligodendrocyte glycoprotein antibodies (MOG-Ab).

Clinical Trials

Clinical Trial
  • Status: Not yet recruiting
  • Intervention Type: Other
  • Participants: 60
  • Start Date: January 2021
Assessment of Emotional Memory During Transient Global Amnesia
Clinical Trial
  • Status: Not yet recruiting
  • Phase: N/A
  • Intervention Type: Device
  • Participants: 96
  • Start Date: November 2020
Efficacy of Dorso-lateral Prefrontal Cortex Stimulation by tDCS in Patients With Motor Conversion Disorder - Multicentre Randomized Double Blind Assay
Clinical Trial
  • Status: Not yet recruiting
  • Participants: 100
  • Start Date: October 15, 2020
MS Screen Test: Using a Smartphone Application to Predict the Prognosis in Patients With Newly Diagnosed Multiple Sclerosis
Clinical Trial
  • Status: Not yet recruiting
  • Intervention Type: Other
  • Participants: 30
  • Start Date: September 2020
Evaluation of the Value of 18F-fluorodeoxyglucose Positron Emission Tomography (FDG PET) and Brain Perfusion Computed Tomography (CT Perfusion) for Predicting the Efficacy of Anti-angiogenic Therapy (Bevacizumab) in Patients With Recurrent Glioblastoma
Clinical Trial
  • Status: Recruiting
  • Intervention Type: Other
  • Participants: 1000
  • Start Date: August 12, 2019
French Registry for Monitoring Pregnancies and Children of Women With Multiple Sclerosis Within The Observatoire Français de la Sclérose en Plaque (OFSEP) Cohort
Clinical Trial
  • Status: Recruiting
  • Intervention Type: Diagnostic Test
  • Participants: 1750
  • Start Date: May 22, 2019
Serum Neurofilament-light Chain Levels in Patients From the OFSEP Cohort at Different Landmarks of Multiple Sclerosis
Clinical Trial
  • Status: Recruiting
  • Phase: N/A
  • Intervention Type: Other
  • Participants: 60
  • Start Date: October 26, 2018
Evaluation of the Prevalence of Oculomotor Disorders in Patients With Radiologically Isolated Syndrome
Clinical Trial
  • Status: Recruiting
  • Participants: 75
  • Start Date: October 11, 2016
Is Protein S100B a Predictor of First-to-chronic Seizure Conversion in Adults? A Prognostic Cohort Study
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 3
  • Intervention Type: Biological, Drug, Other
  • Participants: 316
  • Start Date: July 16, 2013
Multicentric, Randomized, Double-blind Versus Placebo Study Evaluating the Efficacy of Treatment With Cholecalciferol (Vitamin D3) for Delaying the Diagnosis of Multiple Sclerosis (MS) After a Clinically Isolated Syndrome (CIS). Comparison of Conversion Rates After 2 Years.

All Publications
View All

Publication
Study
  • Journal: Revue neurologique
  • Published —
Title Not Found
Publication
Study
  • Journal: Journal of neurology
  • Published —
18F-FDOPA-PET in pseudotumoral brain lesions.

Contact

Nimes, FR

Insurance

Contact them to find out if they accept your insurance plan.